Gyre Therapeutics, Inc. (GYRE) is a San Diego-based biopharmaceutical company whose commercial operations run through its majority-owned Chinese subsidiary, Gyre Pharmaceuticals. Its revenue comes mainly from ETUARY (pirfenidone) for idiopathic pulmonary fibrosis, with smaller contributions from Etorel and Contiva, while its pipeline centers on hydronidone (F351) for liver fibrosis and, following the Cullgen acquisition, targeted protein degraders.
Shares traded at $4.46 late Monday, a gain of $0.15, or 3.48%, from Friday's close of $4.31. The move was upward, but it came without an identifiable company-specific announcement, and it left the stock well below the $7.00 area where it traded as recently as late October.
No verified news or fundamental catalyst found to account for Monday's gain. There was no press release, no fresh regulatory filing, no analyst rating change, no financing, and no corporate announcement published ahead of the session that would justify a re-rating of the equity.
The price action is most consistent with a technical rebound inside a deeply oversold range. The stock collapsed 28.9% on Oct. 30 on very heavy volume and then slid another 9.7% to $4.01 on Nov. 5, a cumulative decline of more than 40% in five sessions that took shares to their lowest level in over a year. Since then, price has chopped between roughly $4.20 and $4.76, and Monday's strength represents a bounce from the lower half of that band rather than the start of a new trend. With average turnover over the past 20 sessions near 114,000 shares, the float is thin enough that modest buying interest can move the quote by several percentage points; the day's volume showed no sign of a large block trade or a sudden influx of institutional demand.
Monday's percentage move was entirely ordinary for this name. Over the prior 60 completed sessions, Gyre's average absolute daily change was about 3.5%, and no fewer than 25 of those sessions produced a move equal to or larger than today's 3.48%. That includes five sessions with double-digit swings in the past month alone. In other words, the gain is noise by the stock's own standards, not an anomaly.
Volume was not elevated in a meaningful way, in contrast to the 220,000-plus share sessions that accompanied the late-October capitulation and the early November bottom. Technically, the stock remains far below its 50-day and 200-day moving averages, both of which sit near $6.80 to $7.00, so the session did not break any meaningful resistance. The shares are also roughly half the 52-week high near $9.14, and the Nov. 5 low around $4.00 is the reference point that now defines downside support.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Gyre earns 6 out of 100.
Both halves of the calculation are weak. No verified fundamental news was published, so catalyst strength sits at the bottom of the scale. The price component is equally subdued: today's gain was about 1.0 times the stock's typical daily move, and comparable or larger moves occurred in roughly 25 of the last 60 sessions. A routine swing in a thinly traded micro-cap, with no news behind it, produces a very low combined reading.
The central event is the Chinese regulatory decision on F351 for hepatitis B-associated liver fibrosis. The application was accepted with priority review in May 2026, and management has guided toward an NMPA decision by year-end 2026 or early in the first quarter of 2027, with a China launch in the first half of 2027 if approved. A favorable ruling would be the first genuine commercial expansion beyond the ETUARY franchise; a delay or a complete response letter would remove the main reason to own the equity near current levels.
Operationally, investors will watch whether ETUARY volume growth continues to offset the margin pressure on Etorel and Contiva from China's centralized procurement program, and whether full-year revenue lands inside the affirmed $100.5 million to $111.0 million range. On the pipeline side, the company has flagged a Phase 2 start for CG001419 in the first half of 2027, Phase 1 dose-escalation data for CG009301 in the second half of 2027, and further dialogue with the FDA on U.S. Phase 2 requirements for F351. Fourth-quarter results are the next scheduled financial checkpoint, and any equity raise would be a key risk given a net loss of $35.3 million through the first nine months of 2026.
Tickeron maintains a curated Trending AI Robots page that surfaces only the strongest-performing automated strategies under current market conditions, drawn from a library of hundreds of bots covering thousands of tickers. Because the bots differ by strategy logic, timeframe, performance metrics, and the symbols they trade, the trending list changes as market conditions shift. For volatile small-caps like this one, it offers a structured way to see which approaches are working right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 32 cases where GYRE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GYRE's RSI Oscillator exited the oversold zone, 36 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 60 cases where GYRE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for GYRE just turned positive on November 17, 2026. Looking at past instances where GYRE's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Following a +5.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where GYRE advanced for three days, in 216 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GYRE as a result. In 81 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
GYRE moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GYRE crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for GYRE entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.676) is normal, around the industry mean (3.592). P/E Ratio (-23.800) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (6.536) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. GYRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology